These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 35867890

  • 1. Repeatability and test-retest reproducibility of mean apparent diffusion coefficient measurements of focal and diffuse disease in relapsed multiple myeloma at 3T whole body diffusion-weighted MRI (WB-DW-MRI).
    ElGendy K, Barwick TD, Auner HW, Chaidos A, Wallitt K, Sergot A, Rockall A.
    Br J Radiol; 2022 Sep 01; 95(1138):20220418. PubMed ID: 35867890
    [Abstract] [Full Text] [Related]

  • 2. Repeatability and reproducibility of apparent diffusion coefficient and fat fraction measurement of focal myeloma lesions on whole body magnetic resonance imaging.
    Barwick T, Orton M, Koh DM, Kaiser M, Rockall A, Tunariu N, Blackledge M, Messiou C.
    Br J Radiol; 2021 Apr 01; 94(1120):20200682. PubMed ID: 33733812
    [Abstract] [Full Text] [Related]

  • 3. Interobserver agreement of whole-body magnetic resonance imaging is superior to whole-body computed tomography for assessing disease burden in patients with multiple myeloma.
    Lai AYT, Riddell A, Barwick T, Boyd K, Rockall A, Kaiser M, Koh DM, Saffar H, Yusuf S, Messiou C.
    Eur Radiol; 2020 Jan 01; 30(1):320-327. PubMed ID: 31267214
    [Abstract] [Full Text] [Related]

  • 4. Diffusion-weighted quantitative MRI of pleural abnormalities: Intra- and interobserver variability in the apparent diffusion coefficient measurements.
    Priola AM, Priola SM, Gned D, Giraudo MT, Brundu M, Righi L, Veltri A.
    J Magn Reson Imaging; 2017 Sep 01; 46(3):769-782. PubMed ID: 28117923
    [Abstract] [Full Text] [Related]

  • 5. Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome.
    De Paepe KN, Van Keerberghen CA, Agazzi GM, De Keyzer F, Gheysens O, Bechter O, Wolter P, Dierickx D, Janssens A, Verhoef G, Oyen R, Koole M, Vandecaveye V.
    Radiol Imaging Cancer; 2021 Mar 01; 3(2):e200061. PubMed ID: 33817648
    [Abstract] [Full Text] [Related]

  • 6. Repeatability and Reproducibility Assessment of the Apparent Diffusion Coefficient in the Prostate: A Trial of the ECOG-ACRIN Research Group (ACRIN 6701).
    Boss MA, Snyder BS, Kim E, Flamini D, Englander S, Sundaram KM, Gumpeni N, Palmer SL, Choi H, Froemming AT, Persigehl T, Davenport MS, Malyarenko D, Chenevert TL, Rosen MA.
    J Magn Reson Imaging; 2022 Sep 01; 56(3):668-679. PubMed ID: 35143059
    [Abstract] [Full Text] [Related]

  • 7. Lung Cancer: Short-Term Reproducibility of Intravoxel Incoherent Motion Parameters and Apparent Diffusion Coefficient at 3T.
    Jiang J, Yin J, Cui L, Gu X, Cai R, Gong S, Xu Y, Ma H, Mao J.
    J Magn Reson Imaging; 2018 Apr 01; 47(4):1003-1012. PubMed ID: 28741732
    [Abstract] [Full Text] [Related]

  • 8. Diffusion-Weighted MRI in Patients with Testicular Tumors-Intra- and Interobserver Variability.
    Pedersen MRV, Loft MK, Dam C, Rasmussen LÆL, Timm S.
    Curr Oncol; 2022 Feb 02; 29(2):837-847. PubMed ID: 35200570
    [Abstract] [Full Text] [Related]

  • 9. Quantitative diffusion-weighted magnetic resonance enterography in ileal Crohn's disease: A systematic analysis of intra and interobserver reproducibility.
    Yu H, Shen YQ, Tan FQ, Zhou ZL, Li Z, Hu DY, Morelli JN.
    World J Gastroenterol; 2019 Jul 21; 25(27):3619-3633. PubMed ID: 31367161
    [Abstract] [Full Text] [Related]

  • 10. Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease burden.
    Giles SL, deSouza NM, Collins DJ, Morgan VA, West S, Davies FE, Morgan GJ, Messiou C.
    Clin Radiol; 2015 Jun 21; 70(6):614-21. PubMed ID: 25799364
    [Abstract] [Full Text] [Related]

  • 11. Diffusion-weighted (DW) MRI in lung cancers: ADC test-retest repeatability.
    Weller A, Papoutsaki MV, Waterton JC, Chiti A, Stroobants S, Kuijer J, Blackledge M, Morgan V, deSouza NM.
    Eur Radiol; 2017 Nov 21; 27(11):4552-4562. PubMed ID: 28396997
    [Abstract] [Full Text] [Related]

  • 12. Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.
    Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis J, Esserman LJ, Hylton NM, ACRIN Trial Team and I-SPY 2 TRIAL Investigators.
    J Magn Reson Imaging; 2019 Jun 21; 49(6):1617-1628. PubMed ID: 30350329
    [Abstract] [Full Text] [Related]

  • 13. Baseline bone marrow ADC value of diffusion-weighted MRI: a potential independent predictor for progression and death in patients with newly diagnosed multiple myeloma.
    Zhang L, Wang Q, Wu X, Zhao A, Feng J, Zhang H, Cao X, Li S, Cai H, Sun Z, Duan M, Zhu T, Zhang W, Jin Z, Zhou D, Xue H, Li J.
    Eur Radiol; 2021 Apr 21; 31(4):1843-1852. PubMed ID: 32965573
    [Abstract] [Full Text] [Related]

  • 14. Assessment and quantification of sources of variability in breast apparent diffusion coefficient (ADC) measurements at diffusion weighted imaging.
    Giannotti E, Waugh S, Priba L, Davis Z, Crowe E, Vinnicombe S.
    Eur J Radiol; 2015 Sep 21; 84(9):1729-36. PubMed ID: 26078100
    [Abstract] [Full Text] [Related]

  • 15. Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction.
    Latifoltojar A, Hall-Craggs M, Bainbridge A, Rabin N, Popat R, Rismani A, D'Sa S, Dikaios N, Sokolska M, Antonelli M, Ourselin S, Yong K, Taylor SA, Halligan S, Punwani S.
    Eur Radiol; 2017 Dec 21; 27(12):5325-5336. PubMed ID: 28656463
    [Abstract] [Full Text] [Related]

  • 16. Diffusion-weighted magnetic resonance imaging for assessment of lung lesions: repeatability of the apparent diffusion coefficient measurement.
    Bernardin L, Douglas NH, Collins DJ, Giles SL, O'Flynn EA, Orton M, deSouza NM.
    Eur Radiol; 2014 Feb 21; 24(2):502-11. PubMed ID: 24275802
    [Abstract] [Full Text] [Related]

  • 17. Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-body Diffusion-weighted MRI with Apparent Diffusion Coefficient: Preliminary Results From a Single-center Study.
    Wu C, Huang J, Xu WB, Guan YJ, Ling HW, Mi JQ, Yan H.
    Acad Radiol; 2018 Jul 21; 25(7):904-914. PubMed ID: 29373210
    [Abstract] [Full Text] [Related]

  • 18. Repeatability and reproducibility of ADC measurements: a prospective multicenter whole-body-MRI study.
    Michoux NF, Ceranka JW, Vandemeulebroucke J, Peeters F, Lu P, Absil J, Triqueneaux P, Liu Y, Collette L, Willekens I, Brussaard C, Debeir O, Hahn S, Raeymaekers H, de Mey J, Metens T, Lecouvet FE.
    Eur Radiol; 2021 Jul 21; 31(7):4514-4527. PubMed ID: 33409773
    [Abstract] [Full Text] [Related]

  • 19. Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma.
    Giles SL, Messiou C, Collins DJ, Morgan VA, Simpkin CJ, West S, Davies FE, Morgan GJ, deSouza NM.
    Radiology; 2014 Jun 21; 271(3):785-94. PubMed ID: 24475858
    [Abstract] [Full Text] [Related]

  • 20. Whole-body diffusion-weighted MRI for evaluation of response in multiple myeloma patients following bortezomib-based therapy: A large single-center cohort study.
    Zhang Y, Xiong X, Fu Z, Dai H, Yao F, Liu D, Deng S, Hu C.
    Eur J Radiol; 2019 Nov 21; 120():108695. PubMed ID: 31589995
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.